I'm LongbridgeAI, I can summarize articles.Amgen rose 2% to $447.09 after Tezspire showed significant remission in Phase 3 eosinophilic esophagitis trial.
Amgen (AMGN.US) climbed more than 2% during regular trading to $447.09, hitting an intraday record high.
The company and AstraZeneca announced positive results from the Phase 3 CROSSING trial of Tezspire for eosinophilic esophagitis. The drug achieved significant histologic remission and sustained symptom reduction over 52 weeks compared with placebo, with a consistent safety profile.
Separately, RBC Capital Markets raised its price target on Amgen to $430 from $400, maintaining an Outperform rating.
Based on public media reports. AI-generated; not investment advice.